MedTrace Logo

OPAL: "Opiates and PhArmacoLogy"

NCT01847729 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 263

Last updated 2018-12-12

No results posted yet for this study

Summary

The aim of this study is to determine the current prevalence of co-addictions, including problem/pathological gambling, in patients receiving Opiate Substitution Treatment (OST), and to then compare patients receiving OST with or without a co-addiction (excluding tobacco dependence) in order to determine their clinical profile.

In addition, an ancillary study to be carried out only among those patients receiving methadone, will aim to etablish whether a low plasma concentration of methadone, on the one hand, and an ultrarapid metabolizer genetic profile, on the other, are the characteristics most commonly associated with the presence of co-addictions. This will allow us to complete patient's pharmacological characterization.

Conditions

  • Substance Use Disorder

Sponsors & Collaborators

  • Nantes University Hospital

    lead OTHER

Principal Investigators

  • Marie Grall-Bronnec, PH · Nantes University Hospital

  • Régis Bouquié, AHU · Nantes University Hospital

  • Stéphane Bézieau, Pr · Nantes University Hospital

  • Pierre Bodenez · University Hospital, Brest

  • Morgane Guillou-Landréat · Morlaix Hospital

  • Bertrand Legeay · Medico-psychological regional service nantes University Hospital

  • Isabelle Martineau · La Métairie center care support and prevention of addiction

  • Philippe Levassor · La Rose des Vents center care support and prevention of addiction

  • Jean-Yves Guillet · General practitioners in the drug-addiction network of the Nantes Area

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-07-11
Primary Completion
2016-07-21
Completion
2016-07-21

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01847729 on ClinicalTrials.gov